Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
October 05 2021 - 8:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that C. Russell Trenary,
President and Chief Executive Officer of Outlook Therapeutics, will
make a company presentation at the OIS Retina Innovation Showcase
and Jeff Evanson, Chief Commercial Officer, will participate in an
industry panel on Thursday, October 7, 2021 in San Antonio, Texas
and virtually.
Details for the presentations are as
follows:
Innovation Showcase: Company
PresentationC. Russell Trenary III, President & Chief
Executive OfficerThursday, October 7, 2021 at 8:55 AM CT
Retina Industry Insights
PanelJeff Evanson, Chief Commercial OfficerThursday,
October 7, 2021 at 4:35 PM CT
For more information and to register for this
event, please visit OIS Retina@ASRS.
About the Ophthalmology Innovation
Summit (OIS) Retina Innovation Showcase
Launched in 2009, the Ophthalmology Innovation
Summit serves to showcase novel therapies in development for unmet
needs in ophthalmic disease and vision disorders, bringing together
entrepreneurs, ophthalmic start-up companies, clinical thought
leaders, industry executives and investment professionals to
facilitate an exchange of information and connections to drive
innovation in the retina, anterior segment, and optometry.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical
company working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved,
Outlook Therapeutics expects to commercialize it as the first and
only FDA-approved ophthalmic formulation of bevacizumab for use in
treating retinal diseases in the United States, United Kingdom,
Europe, Japan and other markets. Outlook Therapeutics expects to
submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA
under the PHSA 351(a) regulatory pathway. For more information,
please visit www.outlooktherapeutics.com.
CONTACTS:Media
Inquiries:Harriet UllmanVice PresidentLaVoie Health
ScienceT: 617-669-3082hullman@lavoiehealthscience.com
Investor Inquiries:Jenene ThomasChief Executive
OfficerJTC Team, LLCT: 833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
From Jul 2023 to Jul 2024